Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H6N2S3 |
InChIKeyCKNAQFVBEHDJQV-UHFFFAOYSA-N |
CAS Registry64224-21-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 3 | KR | 01 Feb 2014 | |
Metabolic dysfunction-associated steatotic liver disease | Phase 3 | KR | 01 Feb 2014 | |
Nonalcoholic Steatohepatitis | Phase 2 | - | - | |
Nonalcoholic Steatohepatitis | Phase 2 | - | - | |
Nonalcoholic Steatohepatitis | Phase 2 | - | - |
Phase 2 | 60 | Placebo | urscndskdi(mjqgyhoxgd) = xnccudodrq slyvhcxwfi (eojrlcwlmc ) View more | - | 01 Apr 2017 | ||
urscndskdi(mjqgyhoxgd) = jowvwjgczd slyvhcxwfi (eojrlcwlmc ) |